|
 |
CaelyxThis page contains recent news articles, when available, and an overview of Caelyx but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Its product range includes Caelyx, Celestone Tablets, Clingard, Dipform, Dipgenta, Diplene, Dipsalic, Elocon, Emolene, Ensamycin, Ethyol, Garamycin, ... TopNews Endocyte Presents Data On EC145 In Treatment Of Ovarian Cancer Before The ... - Oct 22, 2009 ...an international randomized study of EC145 in combination with Doxil®/Caelyx® versus Doxil®/Caelyx® alone in women with platinum-resistant ovarian ... Medical News Today (press release) Schering-Plough Reports Financial Results for 2009 Third Quarter - Oct 22, 2009 ...(5%) REBETOL 64 63 1% 197 193 2% CAELYX 67 80 (16%) 195 232 (16%) INTRON 56 61 (8%) 177 177 -% REMERON 74 61 21% 174 190 (8%) PROVENTIL / ALBUTEROL 59 ... Reuters Cancer drug developer Endocyte extends series C, reins in $26m - Oct 19, 2009 Endocyte Inc, a cancer drug discovery and development company, has closed a $26m extension of its series C financing round. The round included participation ... AltAssets CAELYX Delays Time To Metastatic Breast Cancer Progression - Jun 4, 2007 Results from a Phase III study that showed maintenance chemotherapy with CAELYX significantly prolonged time to progression in patients with metastatic ... emaxhealth.com … Release: Newly-Published Study Shows CAELYX(R) Plus Carboplatin to... - Feb 16, 2007 Newly-Published Study Shows CAELYX(R) Plus Carboplatin to Be Highly Effective and May Potentially Offer Low Neurotoxicity in Patients With Advanced Ovarian ... Pay-Per-View - PR Newswire Europe - HighBeam Research Gynecologic oncology: SP's Caelyx in platinum-sensitive ovarian cancer - Feb 27, 2006 New approaches to the treatment of patients with platinum-sensitive recurrent ovarian cancer were discussed at a conference symposium on "Treatment ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Gynecologic oncology: SP's Caelyx in platinum-sensitive ovarian... - Mar 6, 2006 New approaches to the treatment of patients with platinum-sensitive recurrent ovarian cancer were discussed at a conference symposium on "Treatment ... $4.95 - Pharma Marketletter - ECNext Phase III Trial of YONDELIS(R) (Trabectedin) Initiated in Ovarian... - Apr 4, 2005 Liposomal doxorubicin (CAELYX(R)/DOXIL(R)) already has been approved for this ... As the combination of YONDELIS with CAELYX (DOXIL) also demonstrated ... Free with registration - PR Newswire Europe - AccessMyLibrary.com Press Release: NICE Recommends Caelyx(R) For Newly-Recognised … - May 24, 2005 NICE Recommends Caelyx(R) For Newly-Recognised Group of Advanced Ovarian Cancer Patients. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research SP's Caelyx increases TTP in breast cancer. - Jun 11, 2007 S-P's Caelyx increases TTP in breast cancer. US drugmaker Schering Plough says that its anticancer drug Caelyx (pegylated liposomal doxorubicin HCl) ... $9.94 - Pharma Marketletter - Alacra Store Press Release: CAELYX(R) Delays Time to Disease Progression as … - Jun 3, 2007 CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research CAELYX Schering Plough plans phase III study in older women.( … - Feb 7, 2005 On 26 January 2005 it was announced that a randomized study of Schering Plough's pegylated liposomal formulation of the anthracycline antibiotic, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Strong Ph II data for Schering-Plough's Caelyx. - Mar 5, 2007 US drug major Schering-Plough says that strong clinical data on Caelyx (pegylated liposomal doxorubicin HCl), in combination with carboplatin, was published ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Ovarian Cancer: Platinum-Based Therapy Still the Gold Standard - Sep 11, 2006 There are also other drugs such as Eli Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan) and Ortho Biotech/Schering Plough's Doxil/Caelyx ... RedOrbit NICE: SP's Caelyx only single-agent drug for platinum-sensitive... - May 30, 2005 The National Institute for Health and Clinical Excellence of England and Wales has issued its review guidance on the clinical management for second-line or ... $4.95 - Pharma Marketletter - ECNext US FDA Grants Full Approval To DOXIL(R) For Ovarian Cancer … - Feb 8, 2005 Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market this medication as CAELYX throughout the rest of the world, ... Medical News Today - Medical News Today (press release) SP's Caelyx impresses in Ph II cancer trial. - Feb 26, 2007 S-P's Caelyx impresses in Ph II cancer trial. US drugmaker Schering-Plough says that the results of a Phase II trial of its drug Caelyx (pegylated liposomal ... $9.94 - Pharma Marketletter - Alacra Store … .- Sanidad da luz verde al bortezomib ya 'Caelyx' (Schering-Plouht)... - Jul 15, 2008 De la misma forma, con esta aprobación, se pone de manifiesto la eficacia de Caelyx en el tratamiento de distintos tipos de tumores, puesto que ya está ... ecodiario PharmaMar pide comercialización de Yondelis para cáncer de ovario … - Dec 4, 2008 Medicamentos (EMEA) la comercialización de Yondelis, administrado en combinación con Doxil/Caelyx para el tratamiento de cáncer de ovario refractario. ... ADN.es PharmaMar pide comercialización de Yondelis para cáncer de ovario … - Apr 12, 2008 Medicamentos (EMEA) la comercialización de Yondelis, administrado en combinación con Doxil/Caelyx para el tratamiento de cáncer de ovario refractario. ... Finanzas.com Press Release: Clear Guidance From NICE for Treatment of New Group … - May 24, 2005 The guidance states that Caelyx(R) is the only single agent treatment recommended ... The announcement from NICE also acknowledges that Caelyx(R) is both ... Pay-Per-View - PR Newswire Europe - HighBeam Research … la eficacia del tratamiento basado en CAELYX(R) más carboplatino... - Feb 16, 2007 Este régimen de combinación basado en CAELYX se toleró correctamente en ... "Se está realizando un ensayo internacional con CAELYX para ampliar estos ... elEconomista.es … .-La UE autoriza la combinación de ´Caelyx´ (Schering-Plough) y … - Mar 3, 2008 La Comisión Europea ha autorizado el uso de ´Caelyx´ (doxorrubicina liposomal pegilada) comercializado por Schering-Plough en combinación con bortezomib ... Medicinatv.com Phase III Trial of YONDELIS(R) (Trabectedin) Initiated in Ovarian... - Mar 20, 2005 Liposomal doxorubicin (CAELYX(R)/DOXIL(R)) already has been approved for this ... As the combination of YONDELIS with CAELYX (DOXIL) also demonstrated ... prnewswire.co.uk Empresas. VÃa libre de la EMEA al uso combinado de 'Caelyx' y … - Mar 5, 2008 La Agencia Europea de Medicamentos EMEA ha autorizado el uso de Caelyx -doxorrubicina liposomal pegilada-, de la estadounidense Schering-Plough, ... Diario Médico - Diario Médico (Suscripción) COMUNICADO: Resultados positivos de tres nuevos estudios … - Jun 5, 2006 Schering-Plough Corporation, bajo acuerdo de licencia, tiene los derechos exclusivos para comercializar este medicamento como CAELYX(R) para el resto del ... elEconomista.es Major New Study Focuses on Best Treatment for Older Women with … - Jan 26, 2005 It will also compare Caelyx with another, low-dose combination of anticancer ... Option CAELYX-Nil: -Pegylated liposomal doxorubicin (Caelyx) versus -No ... Free with registration - PR Newswire Europe - AccessMyLibrary.com El NICE recomienda Caelyx® para el tratamiento en segunda lÃnea del … - May 27, 2005 El Instituto Nacional para la Salud y la Excelencia ClÃnica del Reino Unido (NICE, por sus siglas en ingles) ha dado su aprobación definitiva al uso de ... acceso.com Press Release: Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising... - Dec 14, 2006 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: New Patient Study Suggests Siemens Non-Invasive … - Nov 17, 2008 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Weekly ABRAXANE Increased Tumor Response Rate by … - Dec 18, 2006 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Genentech Submits Supplemental Biologics License … - May 25, 2006 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Cancer Treatment; New findings from France, the People's Republic of ... - Sep 5, 2006 Study 1: A recommended dose of pegylated liposomal doxorubicin (Caelyx) in ... Caelyx: 35 (DLI) or 40 (DLII) mg/m2/d1 was followed by 0.5 mg/m2/d topotecan ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Press Release: Kosan Presents Promising Phase 1 Data on Second- … - Jun 4, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Comienza un ensayo internacional con un medicamento en mujeres con … - Apr 4, 2005 Dado que la combinación de "Yondelis" con "Caelyx" también demostró actividad y tolerabilidad en un estudio previo, la base teórica del estudio es que la ... Consumer Press Release: Fujirebio Diagnostics and Roche Diagnostics Sign … - Dec 16, 2008 The guidance states that Caelyx ... category of partially platinum-sensitive ... Article: NICE Recommends Caelyx(R) For Newly-Recognised Group of Advanced . ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: CellSearch(TM) System Cleared for Monitoring Metastatic... - Dec 15, 2006 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Kosan's Second-Generation Hsp90 Inhibitor, … - Sep 10, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Roche to Announce New Breast Cancer Data Pointing to … - Dec 10, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Peregrine Pharmaceuticals Submits Clinical Protocol to... - Sep 10, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Immunicon to Review Scientific Publications and … - Jan 14, 2005 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: About 60 Clinical Studies Regarding Schering-Plough's ... - May 30, 2008 Data will be presented on TEMODAR(R) (temozolomide) Capsules, CAELYX(R) (pegylated ... CAELYX(R): Eleven abstracts will be presented, including two poster ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Xeloda(R) Plus Avastin(R) Combination Delays Disease … - Jun 3, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Journal of Clinical Oncology Publishes Pivotal Phase... - Nov 1, 2005 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Immunicon to Review Scientific Publications and … - Jan 17, 2006 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: FDA Approves ABRAXANE(TM), First in New Class of … - Jan 7, 2005 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Peregrine Pharmaceuticals Submits Clinical Protocol... - Oct 22, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% … - Dec 17, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research About 60 Clinical Studies Regarding Schering-Plough's Oncology … - May 31, 2008 CAELYX(R): Eleven abstracts will be presented, including two poster discussions ... Schering-Plough Corp. has exclusive ex-US marketing rights to CAELYX(R), ... Medical News Today - Medical News Today (press release) Press Release: Mayor's Office Declares October 13 as First Metastatic... - Oct 10, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: HERmark(TM) Assay Results in Metastatic Breast Cancer ... - Dec 14, 2007 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... CAELYX in the treatment of metastatic breast cancer represent an important ... Pay-Per-View - PR Newswire - HighBeam Research Zeltia Group - May 6, 2006 Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market this medication as CAELYX(R) throughout the rest of the world, ... presseportal.ch Schering-Plough brands receive Red Door support - Jan 19, 2006 Brain-cancer treatment Temodal and ovarian cancer brand Caelyx will receive broader ... Caelyx is useful to women allergic to platinum-based compounds. ... PRWeek UK Reacciones alérgicas a los taxanos - May 3, 2007 Debido a lo que parece ser una reacción alérgica, el oncólogo optó por cambiar el tratamiento a Caelyx, pese a que las pruebas de la alergia resultaron ... elmundo.es Combination of Pegylated Liposomal Doxorubicin and Carboplatin … - Nov 2, 2005 Patients who demonstrate a response or stable disease after 6 cycles of Caelyx may receive additional cycles at the investigator's discretion, ... DG News Press Release: Poniard Announces Positive Efficacy and Safety Data … - Jun 1, 2008 Article: ALZA'S CAELYX(R) Approved in Canada for Treatment of Advanced . ... CAELYX(R) (pegylated liposomal doxorubicin hydrochloride) be approved ... the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Court of Appeal Makes Decision Following Ruling That … - May 9, 2008 The announcement from NICE also acknowledges that Caelyx(R) is ... clinically- and cost-effective. This new NICE guidance now clearly recommends Caelyx ... ... Pay-Per-View - PR Newswire Europe - HighBeam Research Equilibre entre avantages et innocuité dans les cancers de l'ovaire... - Oct 30, 2005 CAELYX est la première anthracycline qui affiche un niveau significatif ... CAELYX est particulièrement efficace chez les patientes dont la maladie est ... prnewswire.co.uk MERCK'S IVEMEND, ISENTRESS BACKED BY EUROPEAN HEALTH … - Nov 16, 2007 Caelyx (doxorubicin), from SP Europe, to extend the indication for the ... Caelyx is currently authorised for patients with metastatic breast cancer, ... Bloomberg 折磨三年癌婦苦無藥費 - Feb 25, 2008 ...é†«ç”Ÿæ ¹æ“šå…¶è‡¨åºŠæƒ…æ³?，建è°å¥¹æŽ¥å?—化療藥物Caelyx的治療，她共需接å?—6次化療，æ¯?次 ... Caelyx屬自費藥物，ä¸?在醫院管ç?†å±€çš„資助範åœ?，阿è??所需的化療費æ¯?次13454元， 6 ... è˜‹æžœæ—¥å ± Los marcadores vuelven a elevarse después de un año - Sep 6, 2006 Caelyx a una amiga no le hizo mucho, según me dijo; cisplatino me han dicho que es ... Los más habituales son la adriamicina liposomal (Caelyx®, Myocet®), ... elmundo.es Effect of ultrasound dosimetry on drug release from liposomes- … - Apr 9, 2006 Several liposomal cytotoxic drugs are already commercially available like liposomal doxorubicin (Caelyx®). However, despite an improved tumour accumulation, ... Norges ForskningsrÃ¥d Press Release: RAD001 Shows Potential to Reverse Resistance to … - Dec 12, 2008 Article: Schering-Plough Announces EU Approval of CAELYX(R) in Metastatic ... ... Article: CAELYX(R) Delays Time to Disease Progression as Maintenance ... ... Pay-Per-View - PR Newswire - HighBeam Research Las nuevas antraciclinas permiten extender su uso en mujeres con … - Jun 3, 2005 ..."Caelyx, doxorrubicina liposomal pegilada, tiene la ventaja de presentar una ... Caelyx es un fármaco que actúa con alta especificidad en el tejido tumoral, ... acceso.com EconomÃa/Empresas.- PharmaMar (Zeltia) pide la autorización para … - Dec 4, 2008 Si se aprueba la solicitud para el tratamiento de Yondelis, en combinación con Doxil/Caelyx (doxorrubicina liposomal pegilada), proporcionará a los ... elEconomista.es Press Release: Three New Key Studies at ASCO Highlight Antitumoral … - Jun 5, 2006 This Phase III ... injection) in the US, to a combination of YONDELIS and CAELYX (DOXIL) in ovarian cancer ... hypothesis that combination therapy with ... Pay-Per-View - PR Newswire Europe - HighBeam Research Major New Study Focuses on Best Treatment for Older Women with … - Jan 26, 2005 It will also compare Caelyx with another, low-dose combination of anticancer drugs. Dr. Silvia Dellapasqua, from the IBCSG in Bern, Switzerland, ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: YONDELIS(TM) (trabectedin) Phase II Trials Demonstrate... - May 16, 2005 This Phase III ... injection) in the US, to a combination of YONDELIS and CAELYX (DOXIL) in ovarian cancer ... hypothesis that combination therapy with ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Balancing Benefits with Safety in Breast and Ovarian … - Oct 24, 2005 Based on this concern and promising results from prior clinical trials, CAELYX(R) (pegylated liposomal doxorubicin) is being studied for its efficacy and ... Pay-Per-View - PR Newswire Europe - HighBeam Research PharmaMar pide la autorización para comercializar 'Yondelis' en Europa - May 12, 2008 Si se aprueba la solicitud para el tratamiento de 'Yondelis', en combinación con 'Doxil'/'Caelyx' (doxorrubicina liposomal pegilada), proporcionará a los ... El Confidencial Gebruik dure geneesmiddelen buiten ziekenhuis beperkt - Oct 29, 2007 Alleen Caelyx is per 1 januari 2004 in de beleidsregel dure geneesmiddelen opgenomen. Standaard doxorubicine is generiek beschikbaar en wordt ook buiten het ... Zorgkrant Solicitan comercializar 'Yondelis' en Europa - Dec 4, 2008 Ecteinascidia turbinata, de onde se extrae o Yondelis Se se aproba a solicitude para o tratamento de Yondelis, en combinación con Doxil/Caelyx ... A Nosa Terra COMUNICADO: El IDMC realiza un análisis positivo del ensayo pivotal … - Oct 5, 2006 El estudio pivotal OVA-301 compara la monoterapia con Caelyx(R) (doxorrubicina HCI, inyección liposómica, comercializada como Doxil(R) en Estados Unidos), ... elEconomista.es Zeltia concluye reclutamiento para ensayo fase III de Yondelis con... - Jun 18, 2007 ...conocida como CAELYX® en Europa y DOXIL® (inyección HCI de doxorubicina ... LP, frente a la combinación de YONDELIS® y CAELYX®/DOXIL® en mujeres con ... elEconomista.es Bedeutende neue Studie konzentriert sich auf die beste … - Jan 26, 2005 Sie wird Caelyx mit einer anderen niedrigdosierten Kombination von krebsbekämpfenden Medikamenten vergleichen. Dr. Silvia Dellapasqua von der IBCSG in Bern, ... presseportal.ch Domanda all'esperto del: 02/10/2007 Area Terapeutica: Altro - Oct 2, 2007 La doxorubicina liposomiale (Caelyx®) rientra nella categoria dei farmaci ... Caelyx® può essere utilizzato come chemioterapia sistemica di prima linea o di ... eDott - eDott (Abbonamento) Hohe Ansprechraten mit Doxorubicin-Kombi bei Ovarial-Ca - Jun 28, 2005 Erste Erfolge gibt es nun auch mit der Kombination aus pegyliertem liposomalem Doxorubicin (Caelyx) und Carboplatin. In einer französischen Studie mit 105 ... Ärzte Zeitung Spain's Zeltia signs up patients ahead of schedule - Jun 18, 2007 The study compares the use of doxorubicin -- known as Caelyx in Europe and Doxil in the United States -- with a combination of Zeltia's Yondelis versus ... Reuters Zeltia seeks European OK for ovarian cancer drug - Dec 4, 2008 Zeltia said the drug would be used in the treatment of tumours in conjunction with Doxil-Caelyx. At 1200 GMT, Zeltia shares were up 3.5 percent at 3.8 euros ... Reuters Schering-Plough continues to rise - Apr 7, 2008 ...with just allergy drug Clarinex and chemotherapy treatment Caelyx (totaling 6.3 percent of 2008 sales) exposed to patent losses. ... Boston Globe Drug Makers Stumble on One-Time Charges; Merck's profit, still hurt... - Jul 22, 2005 But revenue surged 18% to $2.5 billion as sales of cancer drug Temodar, arthritis drug Remicade and ovarian cancer drug Caelyx all grew by 30% or more. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Press Release: Patients Who Remain at High Cardiovascular Risk May … - Nov 28, 2007 Article: NICE Recommends Caelyx(R) For Newly-Recognised Group of Advanced ... ... This new NICE guidance now clearly recommends Caelyx(R .. ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Lilly Breast Cancer Studies Explore Potential Role of ... - Jun 3, 2006 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... PR Newswire; March 11, 2004 ; 700+ words ... ... active drugs in the treatment of ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Revised NICE Guidance on Alzheimer's Disease (AD) … - Sep 7, 2007 Article: NICE Recommends Caelyx(R) For Newly-Recognised Group of Advanced ... ... This new NICE guidance now clearly recommends Caelyx(R .. ... Pay-Per-View - PR Newswire Europe - HighBeam Research Article: Breast cancer 5-year survival rates by stage at diagnosis.(DA... - Jul 15, 2005 Article: CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in ... ... Article: CAELYX and Herceptin Combination Shows Activity With Limited ... ... Pay-Per-View - Internal Medicine News - HighBeam Research Press Release: Need to Diagnose and Prevent Cardiac Diseases to … - Feb 7, 2006 Article: NICE Recommends Caelyx(R) For Newly-Recognised Group of Advanced ... ... Caelyx(R) is also approved in the EU as monotherapy for metastatic breast ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Ortho Biotech Seeks FDA Approval for DOXIL(R) in … - Jan 22, 2007 Article: Study Compares DOXIL(R)/CAELYX(R) (Doxorubicin HCL ... PR Newswire; May 20, 2004 ; 700+ words ... ... Results from a new study comparing DOXIL to ... Pay-Per-View - PR Newswire - HighBeam Research Article: Late relapse a concern in tamoxifen/radiotherapy.(Women's … - Mar 15, 2005 Article: CAELYX(TM) and Carboplatin Combination Offers Efficacy and ... PR Newswire; June 7, 2004 ; 700+ words ... ... with advanced ovarian cancer in late ... Pay-Per-View - Family Practice News - HighBeam Research Schering-Plough pushing to reduce reliance on Vytorin - Oct. 1, 2007 - Oct 1, 2007 The company's drugs with patents expiring soonest - the antihistamine Clarinex, with $818 million in 2007 estimated sales, and Caelyx chemotherapy, ... CNNMoney.com Metástasis en el peritoneo - Jan 24, 2006 Le han aplicado dos quimioterapias, taxol+carboplatino y caelyx, continúa con metástasis en el peritoneo. ¿Cómo funcionan éstas? ... elmundo.es Zeltia se la juega de nuevo - Jul 1, 2007 ...en combinación con otro ya existente, el Doxil (Caelyx en Europa), será presentado para su registro ante la EMEA y la estadounidense FDA en 2008. ... El PaÃs - El PaÃs (España) Second Quarter 2007 Results - Jul 23, 2007 Also reporting higher sales in the quarter was CAELYX, up 23 percent to $65 million. Among other prescription products posting higher sales in the 2007 ... Free with registration - PR Newswire - AccessMyLibrary.com EARNINGS | Article from The Record (Bergen County, NJ) | HighBeam … - Oct 25, 2005 The company recorded higher sales for a number of its drugs, including Remicade, used to treat arthritis; Temodar, used to treat brain tumors; Caelyx, ... Pay-Per-View - The Record - HighBeam Research In- Depth Research on Schering-Plough Corp. - Apr 19, 2007 It also offers PEG-INTRON for chronic hepatitis C; INTRON A for chronic hepatitis B and C; TEMODAR for brain tumors; CAELYX for ovarian, sarcoma, ... Free with registration - M2 Presswire - AccessMyLibrary.com è?¯ç‰©é”€å”®ç?«çˆ†å…ˆç?µè‘†é›…第四å£åº¦æ‰äº?为盈 - Jan 31, 2006 ...治疗å?µå·¢è‚¿ç˜¤ã€?乳腺癌和å?¡æ³¢è¥¿æ°?肿瘤的Caelyx第四å£åº¦é”€å”®é¢?劲扬13%，至4600万美元， 主è¦?åŽŸå› æ˜¯è¯¥è?¯è¢«æ™®é??用于å?µå·¢è‚¿ç˜¤å’Œä¹³è…ºç™Œçš„治疗。 ... 新浪网 Schering-Plough swings to profit. - Jan 30, 2006 Sales of Caelyx, for the treatment of ovarian cancer, metastatic breast cancer and Kaposi's sarcoma, rose 13% to $46 million, largely as a result of ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Shareholders alert for Schering-Plough Corp. - Jun 25, 2007 It also offers PEG-INTRON for chronic hepatitis C; INTRON A for chronic hepatitis B and C; TEMODAR for brain tumors; CAELYX for ovarian, sarcoma, ... Free with registration - M2 Presswire - AccessMyLibrary.com Schering-Plough to Expand Its Presence in Latin America, Restructure ... - Jun 21, 2006 ...specialty care products, including PEG-INTRON(R) (peginterferon alfa-2b), TEMODAL(R) (temozolomide) and CAELYX(R) (pegylated liposomal doxorubicin HCl). ... Free with registration - PR Newswire - AccessMyLibrary.com Successful Planned Independent Analysis of Pivotal Phase III Trial of... - Oct 5, 2006 ...to a combination of YONDELIS(R) and CAELYX(R) (DOXIL(R)) in ovarian cancer patients who have relapsed after receiving standard first-line chemotherapy. ... ots.at Twelve DOXIL(R) Clinical Studies to be Presented at American Society... - Dec 7, 2007 Rooms C303-C305 (simultaneous oral session) -- Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL/CAELYX) and Dexamethasone in the Treatment ... Free with registration - PR Newswire - AccessMyLibrary.com Ortho Biotech Seeks FDA Approval For DOXIL(R) In Combination With … - Jan 23, 2007 Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX(R) throughout the rest of the world, ... Medical News Today - Medical News Today (press release) => Successful Planned Independent Analysis of Pivotal Phase III Trial... - May 10, 2006 ...to a combination of YONDELIS(R) and CAELYX(R) (DOXIL(R)) in ovarian cancer patients who have relapsed after receiving standard first-line chemotherapy. ... FinanzNachrichten.de Women Touched By Ovarian Cancer Saluted at 'Celebrating Survivors' … - Sep 20, 2005 Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market this medication as CAELYX(R) throughout the rest of the world, ... RedOrbit |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |